Medpace (NASDAQ:MEDP) Issues Earnings Results

Medpace (NASDAQ:MEDP - Get Free Report) posted its quarterly earnings results on Monday. The company reported $3.67 EPS for the quarter, topping analysts' consensus estimates of $3.06 by $0.61, Zacks reports. Medpace had a net margin of 19.17% and a return on equity of 51.48%. The business had revenue of $558.57 million during the quarter, compared to analysts' expectations of $528.38 million. During the same period last year, the company posted $3.20 earnings per share. Medpace updated its FY 2025 guidance to 12.260-13.040 EPS.

Medpace Trading Down 1.4 %

Shares of MEDP stock traded down $4.33 during trading on Friday, hitting $298.55. The company's stock had a trading volume of 399,606 shares, compared to its average volume of 339,939. The business has a fifty day moving average of $313.79 and a 200-day moving average of $331.70. Medpace has a 52 week low of $250.05 and a 52 week high of $459.77. The company has a market cap of $9.02 billion, a PE ratio of 23.64, a P/E/G ratio of 3.81 and a beta of 1.46.

Analyst Upgrades and Downgrades

MEDP has been the subject of a number of research analyst reports. Truist Financial decreased their target price on Medpace from $333.00 to $300.00 and set a "hold" rating for the company in a research report on Wednesday. William Blair restated a "market perform" rating on shares of Medpace in a report on Tuesday. Mizuho cut their target price on Medpace from $400.00 to $355.00 and set an "outperform" rating on the stock in a report on Wednesday, April 9th. TD Cowen lowered shares of Medpace from a "buy" rating to a "hold" rating and decreased their price target for the company from $370.00 to $328.00 in a research note on Monday, April 14th. Finally, Leerink Partners began coverage on shares of Medpace in a research note on Monday, March 24th. They issued a "market perform" rating and a $330.00 price objective on the stock. Eleven investment analysts have rated the stock with a hold rating and three have given a buy rating to the company's stock. According to data from MarketBeat, Medpace has an average rating of "Hold" and a consensus price target of $349.30.

Medpace Company Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.